BioSpace News Archive

Drug Development

Genentech’s Late-Stage Trial Data Shows Combination of Tecentriq and Avastin Helps NSCLC Patients Live Longer

Genentech is planning to seek regulatory approval for a blended lung cancer treatment following positive interim results from a late-stage trial that showed a combination of Tecentriq and Avastin plus chemotherapy enabled patients to live longer.

March 26, 2018
·
2 min read
·
Alex Keown
Drug Development

Stock Plunges Despite Biohaven’s Positive Migraine Data

Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading this morning.

March 26, 2018
·
3 min read
·
Mark Terry
Drug Development

Protagonist Craters After Discontinuing Phase IIb Ulcerative Colitis Study

Shares of Protagonist Therapeutics plunged more than 60 percent in pre-market trading after the company announced it will discontinue its Phase IIb ulcerative colitis treatment after a review from an Independent Data Monitoring Committee (DMC).

March 26, 2018
·
2 min read
·
Alex Keown
Drug Development

Allecra Therapeutics New Antibiotic Shows Promise for Resistant Bacterial Infections

Allecra Therapeutics released positive top-line data from its Phase II trial of AAI101, an antibiotic against gram-negative bacteria.

March 26, 2018
·
3 min read
·
Mark Terry
Business

Ablynx Drug Fails Again in Mid-Stage Trial

For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.

March 26, 2018
·
2 min read
·
Alex Keown
Career Advice

Is Social Media Preventing You From Advancing at Work?

Whether you’re looking for a new job, negotiating for more pay or responsibility, or seeking to make the transition to a management or leadership position, your presence on social media makes up a large component of your overall professional “brand.”

March 26, 2018
·
5 min read